Nuo Therapeutics Inc
nuot.comWhat Do They Do?
Sells Aurix, a system that prepares a platelet-based wound treatment from a patient’s blood, to hospital wound clinics and private-practice physicians treating chronic wounds.
10-K for FY2025, filed Mar 30, 2026
How Do They Make Money?
Nuo sells products directly and through distributors, with product sales counted when the goods ship; Smith+Nephew paid an upfront distribution-rights fee that Nuo earns over the agreement term.
10-K for FY2025, filed Mar 30, 2026We provide for the sale of our products, including disposable processing sets and supplies through our distribution agreements and directly…View ↗
As consideration for entering into the Distribution Agreement, Smith+Nephew paid us an upfront distribution fee of $1,500,000 for…View ↗
Our distribution agreement with Smith+Nephew (See Note 4 – Distribution Agreement with Smith + Nephew for additional information) provides…View ↗
$3.3M
-
10-K for FY2025, filed Mar 30, 2026
$3.3M ↗
Who Are Their Customers?
Nuo sells Aurix to hospital outpatient wound clinics and private-practice physicians, directly and through distributors; it also supplies Smith+Nephew with a private-label product for distribution.
10-K for FY2025, filed Mar 30, 2026Our revenues are derived from the sale of the Aurix product to customers consisting primarily of hospital outpatient wound care clinics and…View ↗
We provide for the sale of our products, including disposable processing sets and supplies through our distribution agreements and directly…View ↗
On March 31, 2025, we entered into a Distribution Agreement (the “Distribution Agreement”) with a U.S. affiliate of Smith & Nephew PLC…View ↗
Do Revenues Turn Into Profits?
No. It lost $2.5M in FY2025.
10-K for FY2025, filed Mar 30, 2026
−$2.5MView ↗
10-K for FY2025, filed Mar 30, 2026
−$2.5MView ↗
10-K for FY2025, filed Mar 30, 2026
−$1.1MView ↗
How Are They Changing?
Private-label distribution
The older report describes Aurix sales to wound-care clinics through a distributor network; the latest adds a private-label Aurix product supplied to Smith+Nephew, while Nuo continues selling its own brand.
10-K for FY2022, filed Apr 17, 2023 10-K for FY2025, filed Mar 30, 2026
Broader customer focus
The older report emphasized hospital outpatient wound-care clinics; the latest describes broadening relationships with private-office wound-care providers while continuing outreach to hospitals and hospital systems.
10-K for FY2022, filed Apr 17, 2023 10-K for FY2025, filed Mar 30, 2026Our current commercial focus is establishing engagement with providers treating chronic non-healing wounds to demonstrate the clinical…View ↗
As of December 31, 2025, we had established contractual relationships with more than 200 third-party entity and individual representatives.…View ↗
Who Do They Compete With?
Competes with Smith+Nephew, 3M, MoInlycke, ConvaTec, MiMedx, Organogenesis, and Integra Life Sciences
10-K for FY2025, filed Mar 30, 2026While Aurix faces competition in the chronic wound care market from any other FDA cleared platelet derived products, we also face…View ↗
Loading...
